Mylan Pharmaceuticals Inc. has launched Paroxetine Hydrochloride (HCl) extended-release (ER) tablets, the generic version of GlaxoSmithKline's (GSK) Paxil CR.

Mylan has earned 180 days of marketing exclusivity for the 12.5 mg and 25 mg tablets and has the right to market the 37.5 mg strength.  Paroxetine HCl ER tablets had US sales of approximately $301 million for the 12 months ending March 31, 2008, for all three strengths. Earlier Mylan announced the settlement of patent litigation involving Paroxetine HCl ER.